

Indonesia Morning Cuppa

Top Story

Semen Indonesia (SMGR IJ, BUY, TP:9,300)

Margin To Rise But Promotion Cost To Follow; BUY

Results Review

Keep BUY, with new IDR9,300 TP from IDR10,500, 51% upside and c.2% yield. Excluding Semen Baturaja's contribution, Semen Indonesia's FY22 sales volume fell 13.7% while revenue dropped 1.3% – below our and Street estimates. Market fears linger on the risk of a price war as coal prices have fallen YTD, SMGR's share price also plummeted 6.1% yesterday. The company will likely increase its promotion cost instead of lowering ASP. As such, we soften our FY23-24F earnings by 4-9.4%.

Analysts: Ryan Santoso +6221 5094 0983, Andrey Wijaya +6221 5093 9846

Today's Report: [Semen Indonesia : Margin To Rise But Promotion Cost To Follow \(16 Mar 2023\)](#)

Previous Report: [Semen Indonesia : Synergies With Semen Baturaja; Maintain BUY \(3 Feb 2023\)](#)

Indonesia Market Wrap


The JCI was down at 0.21% DoD. Most sectors traded in red territory, with the biggest decreases seen in IDX Basic Industry (-0.96%), IDX Infrastructure (-0.95%), and IDX Technology (-0.92%). The only increases were from IDX Transport (+1.02%) and IDX Property (+0.33%).

Foreigners printed a net buy in the Indonesian market at IDR1.31trn, with net sell of IDR552.82bn in the regular market and net buy of IDR1.86trn in the negotiable market. They bought Bumi Resources (BUMI, +1.63%), Merdeka Copper Gold (MDKA, -0.25%), Sumber Alfaria Trijaya (AMRT, +0.35%), Erajaya Swasembada (ERAA, -0.41%), and Indocement Tunggal Prakarsa (INTP, -6.82%) – among others – while selling Bank Central Asia (BBCA, flat), Bank Rakyat Indonesia (BBRI, -0.21%), Astra International (ASII, flat), Bank Mandiri (BMRI, +1.26%), and Bank Negara Indonesia (BBNI, +0.28%).

The market traded on a good volume of 17.35bn shares worth IDR12.68trn. The top JCI movers were BMRI (+1.26%), Mitra Adiperkasa (MAPI, +5.46%), Surya Esa Perkasa (ESSA, +4.26%), Bumi Serpong Damai (BSDE, +4.74%), and Aneka Tambang (ANTM, +2.20%).

Laggards: Semen Indonesia (SMGR, -6.08%), INTP (-6.82%), Indofood CBP Sukses Makmur (ICBP, -3.37%), Sarana Menara Nusantara (TOWR, -3.66%), and Perusahaan Gas Negara (PGAS, -4.08%).

On the currency side, the IDR appreciated against the USD, trading at IDR15,365 (-0.13%; YTD: -1.3%), while Indonesia's 10-year yield was up at 6.766 (+0.55%).

Chart 1: Industry group relative to the JCI (% YTD changes)

Table 1: Regional markets (15 Mar 2023)

Bloomberg Code	Last value	DoD (%)	YTD (%)	YoY (%)
Dow Jones : DJI	31,875	(0.9)	(3.8)	(5.0)
Nasdaq : Nasdaq	11,434	0.1	9.2	(11.7)
UK : FTSE	7,344	(3.8)	(1.4)	0.7
Hong Kong : HSI	19,540	1.5	(1.2)	(2.7)
Indonesia : JCI	6,628	(0.2)	(3.2)	(5.2)
MSCI : EIDO	22	(1.6)	(3.5)	(12.6)
Malaysia : FBMKLCI	1,404	0.7	(6.1)	(10.7)
Korea : KOSPI	2,380	1.3	6.4	(10.5)
Philippines : PCOMP	6,466	1.1	(1.5)	(8.0)
Thailand : SET	1,565	2.7	(6.2)	(6.2)
China : SHCOMP	3,263	0.6	5.6	2.9
Singapore : STI	3,173	1.4	(2.4)	(3.6)

Note: *Data as at 15 Mar 2023's close

Table 2: Commodities & currencies (15 Mar 2023)

	Last Value	DoD (%)	YTD (%)	YoY (%)	MoM (%)
Oil Price (Brent)	73.7	(4.9)	(14.2)	(26.2)	(13.7)
Oil Price (WTI)	67.6	(5.2)	(15.0)	(28.2)	(13.1)
Coal Price (USD/ton)	175.0	(2.8)	(56.7)	(49.4)	(20.4)
CPO Price (MYR/ton)	4,017	0.9	(6.2)	(35.5)	(3.8)
Soy Oil Price (USD/ton)	56	0.9	(11.7)	(23.5)	(8.0)
Nickel (USD/ton)	22,788	(0.2)	(23.8)	-	(12.0)
Tin (USD/ton)	22,278	(2.0)	(10.0)	(48.2)	(15.8)
Gold (USD/oz)	1,919	0.8	5.3	(0.3)	4.6
Wheat (USD/bu)	703	0.9	(12.0)	(23.0)	(9.9)
Corn (USD/bu)	627	0.9	(7.6)	(3.3)	(7.0)
USD/IDR	15,365.0	0.1	1.3	(6.7)	(1.0)
EUR/IDR	16,504.4	(0.2)	0.7	(4.4)	(1.2)
HKD/IDR	1,959.5	0.1	1.9	(6.6)	(1.1)
SGD/IDR	11,449.1	(0.3)	1.4	(8.4)	(0.4)
JPY/IDR	114.2	0.4	3.4	6.5	(0.2)
MYR/IDR	3,430.3	0.0	2.9	(0.7)	0.9
THB/IDR	444.0	0.1	1.2	(3.5)	(0.6)

Bulletins

STOCK/SECTOR	NEWS	COMMENTS	RATING
Bank Negara Indonesia (BBNI IJ)	<p>Bank Negara Indonesia will distribute dividends amounting to IDR7.3tn or IDR393 per share. The dividend distribution schedule is as follows:</p> <ul style="list-style-type: none"> i. Cum-dates: 27 Mar 2023 (regular market) and 29 Mar 2023 (cash market); ii. Recording date : 29 Mar 2023; iii. Payment date : 14 Apr 2023. <p>(Company)</p>	<p>BBNI's FY22 dividend is a 169% increase from its IDR146 per share distribution for FY21. The higher DPS reflects not only the robust 68% YoY growth in FY22 earning, but also the higher payout of 40% vs 25% for the previous years.</p> <p>The FY22 DPS beats our forecast of IDR363 per share based on a payout of 37%. We maintain our call and TP for BBNI.</p>	<p>BUY, TP: IDR12,000</p>
Cement Indocement Tunggal Prakarsa (INTP IJ) Semen Indonesia (SMGR IJ) Semen Baturaja (SMBR IJ)	<p>February's domestic cement demand contracted 2.6% YoY and 8.5% MoM at 4.5m tonnes while 2M23 domestic sales stood at 9.4m tonnes (-4.9% YoY) – dragged down by a longer period of heavy rainfall than in previous years. Bag market is down 7.6% YoY but bulk market rose 3.4% YoY.</p> <p>However, Indocement Tunggal Prakarsa (INTP) recorded a volume growth of 6.8% YoY in Feb and 4.3% in 2M23, gaining market share in eastern Indonesia from the Maros plant. It increased its market share to 28.2% in 2M23 (2M22: 25.7%), with total sales volume of 2.65m tonnes.</p> <p>Semen Indonesia (SMGR) has also gradually increased its market share to 51.4% (2M22: 50.9%). However, its domestic volume was still down 3.9% at 4.8m tonnes – this total includes the volume from its subsidiary Semen Baturaja (SMBR). (Company)</p>	<p>Due to the prolonged rainy season and start of the fasting period, we expect the national cement demand to be under pressure in 1H23, and to improve after <i>Lebaran</i>. The correcting coal price would benefit INTP in its margins improvement.</p> <p>We maintain our cement sector call, with INTP as our top pick. We also retain our TPs and recommendations of INTP and SMGR. We do not cover SMBR at this time.</p>	<p>Sector: OVERWEIGHT</p> <p>Stocks: INTP: BUY, TP: IDR 12,500</p> <p>SMGR: BUY, TP: IDR 10,500</p> <p>SMBR: NOT RATED</p>

Astra International (ASII IJ)

Astra Otoparts (AUTO IJ)

Astra International (ASII) is focusing on its current core businesses for expansion by considering sustainability aspects. On the automotive, ASII is introducing two 2-wheeler (2W) EV models in 2023 and four in 2024. In the finance front, there will be development in Bank Jasa Jakarta's digital banking, as well as co-operation with WeLab. For the heavy equipment & mining contractor segment, ASII expects to see sustainability-based business development, eg mining minerals and renewable energy. For infrastructure, it is expected to post meaningful earnings contributions in 2024. In the healthcare segment, ASII is looking at the development of a healthcare ecosystem.

In 2023, ASII estimates that national 4-wheeler (4W) wholesales will reach c.1m units, with the company having a >50% market share. YTD, ASII has increased suggested retail price 2% on a better sales mix by introducing new Agya. It estimates national 2W vehicles wholesales to grow at single-digit levels – reaching 5.4-5.5m units – with ASII contributing sales of 4.4-4.5m units. The company currently sells two 4W EV models: The Lexus UMX-300e and bZ4x. It is about to introduce a new model – the Lexus RX. ASII also sells plug-in and normal hybrid models with 13 models already ready for sale. Astra Otoparts (AUTO) is developing the EV charging stations for ASII, targeting 200 charging facilities in the latter's outlets and 20 charging stations in public facilities. AUTO is also ready to supply EV spare parts when it has reached economies of scale.

ASII is also developing a digital banking ecosystem that targets retail and SME businesses. The new ecosystem will be connected to ASII and WeLab's existing systems. At present, ASII Financial has more than 25m customers. The company is also allocating around IDR40trn capex in 2023. Last year, it disbursed IDR26.4trn capex – higher than 2019's pre-pandemic level and almost double of 2021's amount. The 2022 capex was for heavy equipment, Arkora and Bank Jasa Jakarta's acquisitions, toll road investment (with ASII owning 396km of toll roads in eight sections), a 7.45% stake acquisition in Hermina, and a JV Toyota for commercial vehicles' mobility. *(Company)*

Despite rising competition, we have a positive outlook on ASII's 4W and 2W wholesales, which should partially offset lower coal and its related business segments.

The company's strategy to diversify should stabilise earnings in the long term. It is well-supported and will further expand its business. The majority of this year's capex is likely to be spent on heavy equipment and mining – especially non-coal businesses like nickel and its processing facilities.

We maintain our call and TP on ASII, as well as AUTO's.

Stocks:

ASII:
BUY,
TP: IDR7,750

AUTO:
BUY,
TP: IDR2,200

Top BUYs

	TP (IDR)	Upside (%)	Catalysts
Bank Negara Indonesia (BBNI IJ)	12,000	36.4	<ul style="list-style-type: none"> • Management is optimistic that the bank remains on track to achieve its FY22 targets, with the domestic economic recovery and higher commodity prices cushioning the impact of higher inflation and interest rates from 2H22. • The cancellation of its planned rights issue has removed an overhang, pushing the share price up by a sharp 41% YTD. • We expect the stock to move higher, given its still-undemanding P/BV of 1.2x and improving ROEs.
Bank Rakyat Indonesia (BBRI IJ)	5,800	23.4	<ul style="list-style-type: none"> • Our TP implies a P/BV of 2.0-1.8x for FY22-23F. • We expect BBRI to post better 2Q22 earnings, driven by higher interest income (from faster loan growth) and lower interest expenses on the back of lower COF (from a higher CASA ratio). • Based on the most recent monthly financial results, its 5M22 PPOP increased 31% YoY, reaching 46.5% of our full-year projections. • Its 5M22 loan bookings accelerated, rising 9.5% YoY (1Q22: 6.8% YoY) due to increased economic activity in 2Q22.
Indofood CBP (ICBP IJ)	12,500	34.0	<ul style="list-style-type: none"> • The stock is our consumer staples Top Pick, given its dominant market share. • This provides ICBP with strong bargaining power to pass on cost increases without risking volume growth. • Its Pinehill asset also presents ample growth potential.
United Tractors (UNTR IJ)	32,600	19.6	<ul style="list-style-type: none"> • We are optimistic about a positive growth trajectory for UNTR's earnings this year, on the back of higher heavy equipment (HE) sales projections (FY22 target: 5,300 units; +72% YoY). • Strong demand from the revival in mining activities has brought back positive sentiment for the company's domestic HE sales and boosted its market share.
Mayora Indah (MYOR IJ)	3,000	13.2	<ul style="list-style-type: none"> • We are still positive on MYOR, especially post 1H22 results, based on margin recovery following two price increases in 2022. • The company has become a key beneficiary of domestic and overseas border reopenings (mainly China), and the IDR's depreciation.

Recent Stories

To access the following reports, please click on the link:

[Indonesia Morning Cuppa 15 March 2023](#)

[Jayamas Medica Industri : Envisioning a Healthier Future](#)

[Indonesia Morning Cuppa 14 March 2023](#)

[Market Strategy : Be Defensive Now, Focus On Cyclical Sectors In 2H](#)

[Indonesia Mid-Morning Cuppa 13 March 2023](#)

[Auto & Autoparts : Ground Checks: 4W EVs Becoming More Prominent](#)
[Plantation : Wet Weather Hampered Output In February](#)

[Indonesia Morning Cuppa 10 March 2023](#)

[Bukit Asam : Sturdy Operations Vs Headwinds; D/G NEUTRAL](#)

[Indonesia Morning Cuppa 9 March 2023](#)

[Indo Tambangraya : Inevitable Risk From Downtrend; Now NEUTRAL](#)
[Plantation : Diverse Views At POC 2023](#)

[Indonesia Morning Cuppa 8 March 2023](#)

[Arwana Citramulia : New Plant To Boost Sales Mix; Keep BUY](#)

[Indonesia Morning Cuppa 7 March 2023](#)

[Puradelta Lestari : Record-High Margin, Upbeat Earnings; Keep BUY](#)

[Indonesia Morning Cuppa 6 March 2023](#)

[Indonesia Consumer : Consumer Week KTA: Still Upbeat On Consumption](#)
[Retailing : Consumer Week KTA: Malls Seeing a Pick-Up](#)
[Consumer Staples : Consumer Week KTA: FMCGs Still Resilient](#)
[Kalbe Farma : Consumer Week KTA: Steady Margins Ahead](#)
[Mayora Indah : Consumer Week KTA: Blue Skies Throughout; BUY](#)
[Indofood CBP : Consumer Week KTA: Set To Meet Targets; BUY](#)

[Indonesia Morning Cuppa 3 March 2023](#)

[Jasa Marga: Upbeat Earnings From Divestment; Keep BUY](#)

[Indonesia Morning Cuppa 2 March 2023](#)

[Indonesia Banks : Optimistic On 2023 Outlook Despite Soft 4Q; O/W](#)
[Nippon Indosari : Stellar 4Q22 Results; Reiterate BUY](#)
[PP London Sumatra Indonesia : Decent Year-End Boosted By Tax-Free Levy Period](#)

[Indonesia Morning Cuppa 1 March 2023](#)

[Wismilak Inti Makmur : Beneficiary Of Lower Excise Tax](#)

[Indonesia Mid-Morning Cuppa 28 February 2023](#)

[United Tractors : FY22: Stellar Achievements, Cautious Outlook; BUY](#)
[Bank BJB : 2023F: Positive Loan Growth, Lower NIM; Still BUY](#)
[Astra International : Robust FY22 Earnings, Dividends; Keep BUY](#)

[Indonesia Morning Cuppa 27 February 2023](#)

[Matahari Department Store : KTA From Earnings Call](#)

[Indonesia Morning Cuppa 24 February 2023](#)

[Astra Otoparts : Robust Earnings Likely To Continue In 1Q23; BUY](#)
[Astra Agro Lestari : Decent Year End, But Valuation Still Lofty](#)

[Indonesia Morning Cuppa 23 February 2023](#)

[Jasa Marga : A Favoured Stock For Its Heavy Traffic; Keep BUY](#)

[Indonesia Morning Cuppa 22 February 2023](#)

[XL Axiata : In-line 4Q22 Results; Keep BUY](#)
[Kalbe Farma : KTA from Analyst Meeting](#)

[Indonesia Morning Cuppa 21 February 2023](#)

[Victoria Care Indonesia : The Sweet Smell Of Victory](#)

RHB Guide to Investment Ratings

Buy:	Share price may exceed 10% over the next 12 months
Trading Buy:	Share price may exceed 15% over the next 3 months. however longer-term outlook remains uncertain
Neutral:	Share price may fall within the range of +/- 10% over the next 12 months
Take Profit:	Target price has been attained. Look to accumulate at lower levels
Sell:	Share price may fall by more than 10% over the next 12 months
Not Rated:	Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof .i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and .ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated event. The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Bhd. The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHB Investment Bank Bhd has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

Please refer to the following link, ([RHB Research conflict disclosures – Mar 2023](#)) and the Disclosure of Conflict of Interest in each of the research reports provided in this email for more details.

Kuala Lumpur

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur
Malaysia
Tel : +.60) 3 9280 8888
Fax : +.60) 3 9200 2216

Singapore

RHB Bank Berhad (Singapore branch)
90 Cecil Street
#04-00 RHB Bank Building
Singapore 069531
Fax: +65 6509 0470

Jakarta

PT RHB Sekuritas Indonesia
Revenue Tower, 11th Floor, District 8 - SCBD
Jl. Jendral Sudirman Kav 52-53
Jakarta 12190
Indonesia
Tel : +6221 509 39 888
Fax : +6221 509 39 777

Bangkok

RHB Securities (Thailand) PCL
10th Floor, Sathorn Square Office Tower
98, North Sathorn Road, Silom
Bangrak, Bangkok 10500
Thailand
Tel: +.66) 2 088 9999
Fax : +.66) 2 088 9799